Glaukos (NYSE: GKOS)
Glaukos Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Glaukos Company Info
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.
News & Analysis
Why Glaukos Stock Zoomed Nearly 19% Higher Today
Investors were cheered by the latest update from the lab.
Why Glaukos Stock Is Soaring Today
CMS' final payment rates for 2022 spurred an analyst upgrade for Glaukos.
Why Glaukos Stock Sank Today
An analyst downgraded the healthcare stock.
Why Glaukos Stock Is Tanking Today
Proposed rates from CMS for fiscal 2022 weren't what investors expected.
3 Top Mid-Cap Stocks to Buy Right Now
Investors would be wise to steer clear of the bigger, more mainstream names until the recent volatility has run its course
Why Glaukos Stock Plunged 21% in August
Acquisition news was the culprit behind the hit to shares of the ophthalmic medical technology and pharmaceutical company.
Avedro and Glaukos Join Forces
Glaukos makes a bid for Avedro in an all-stock transaction.
Why Glaukos Stock Jumped 16.3% in February
Shares of this mid-cap ophthalmic medical tech and pharmaceutical company have soared 111% over the last year.
Valuation
Earnings Transcripts
Glaukos Corp (GKOS) FY 2021 Earnings Call Transcript
GKOS earnings call for the period ending November 29, 2021.
Glaukos Corp (GKOS) Q3 2021 Earnings Call Transcript
GKOS earnings call for the period ending October 31, 2021.
Glaukos Corp (GKOS) Q2 2021 Earnings Call Transcript
GKOS earnings call for the period ending June 30, 2021.
Glaukos Corp (GKOS) Q1 2021 Earnings Call Transcript
GKOS earnings call for the period ending March 31, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.